Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia
- Author
- Stien De Coninck, Juliette Roels (UGent) , Béatrice Lintermans (UGent) , Sara T'Sas (UGent) , Tom Taghon, David Curtis, Tim Pieters (UGent) , Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)
- Organization
- Project
-
- The role of TET2 in (pre)-leukemic T-cell acute lymphoblastic leukemia
- Targeting transcription factor addiction in acute leukemia (TaTFAL)
- TET2 to the rescue in T-ALL
- Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.
- Role of TET2 in (pre)-leukemic T-ALL: TET2 to the rescue?
- Keywords
- DNA METHYLATION, MICE, ORIGIN
Downloads
-
publisher version.pdf
- full text (Published version)
- |
- open access
- |
- |
- 597.23 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HXVCP23WD4H60A1MQYS680RM
- MLA
- De Coninck, Stien, et al. “Tet2 Is a Tumor Suppressor in the Pre-Leukemic Phase of T-Cell Acute Lymphoblastic Leukemia.” BLOOD ADVANCES, vol. 8, no. 11, 2024, pp. 2646–49, doi:10.1182/bloodadvances.2023011970.
- APA
- De Coninck, S., Roels, J., Lintermans, B., T’Sas, S., Taghon, T., Curtis, D., … Van Vlierberghe, P. (2024). Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia. BLOOD ADVANCES, 8(11), 2646–2649. https://doi.org/10.1182/bloodadvances.2023011970
- Chicago author-date
- De Coninck, Stien, Juliette Roels, Béatrice Lintermans, Sara T’Sas, Tom Taghon, David Curtis, Tim Pieters, Steven Goossens, and Pieter Van Vlierberghe. 2024. “Tet2 Is a Tumor Suppressor in the Pre-Leukemic Phase of T-Cell Acute Lymphoblastic Leukemia.” BLOOD ADVANCES 8 (11): 2646–49. https://doi.org/10.1182/bloodadvances.2023011970.
- Chicago author-date (all authors)
- De Coninck, Stien, Juliette Roels, Béatrice Lintermans, Sara T’Sas, Tom Taghon, David Curtis, Tim Pieters, Steven Goossens, and Pieter Van Vlierberghe. 2024. “Tet2 Is a Tumor Suppressor in the Pre-Leukemic Phase of T-Cell Acute Lymphoblastic Leukemia.” BLOOD ADVANCES 8 (11): 2646–2649. doi:10.1182/bloodadvances.2023011970.
- Vancouver
- 1.De Coninck S, Roels J, Lintermans B, T’Sas S, Taghon T, Curtis D, et al. Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia. BLOOD ADVANCES. 2024;8(11):2646–9.
- IEEE
- [1]S. De Coninck et al., “Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia,” BLOOD ADVANCES, vol. 8, no. 11, pp. 2646–2649, 2024.
@article{01HXVCP23WD4H60A1MQYS680RM,
author = {{De Coninck, Stien and Roels, Juliette and Lintermans, Béatrice and T'Sas, Sara and Taghon, Tom and Curtis, David and Pieters, Tim and Goossens, Steven and Van Vlierberghe, Pieter}},
issn = {{2473-9529}},
journal = {{BLOOD ADVANCES}},
keywords = {{DNA METHYLATION,MICE,ORIGIN}},
language = {{eng}},
number = {{11}},
pages = {{2646--2649}},
title = {{Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia}},
url = {{http://doi.org/10.1182/bloodadvances.2023011970}},
volume = {{8}},
year = {{2024}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: